- Home
- NMG vs EVMN Comparison
NMG vs EVMN Comparison
Compare NMG & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NMG | EVMN |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 456.6M | 529.6M |
| IPO Year | 2017 | 2025 |
Fundamental Metrics
Financial Performance| Metric | NMG | EVMN |
|---|---|---|
| Price | $2.35 | $18.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $4.16 | ★ $39.17 |
| AVG Volume (30 Days) | ★ 967.0K | 364.0K |
| Earning Date | 11-12-2025 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,000,000.00 |
| Revenue This Year | N/A | $89.43 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 160.00 |
| 52 Week Low | $1.30 | $13.89 |
| 52 Week High | $6.06 | $24.03 |
Technical Indicators
Market Signals| Indicator | NMG | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 34.70 | 46.77 |
| Support Level | $2.87 | $17.67 |
| Resistance Level | $3.12 | $23.33 |
| Average True Range (ATR) | 0.19 | 2.10 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 2.23 | 23.83 |
Price Performance
Historical ComparisonAbout NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The company currently operates in two segments: the Matawinie Mine Project and the Battery Material Plant project.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.